Prognosis and Safety of rt-PA Intravenous Thrombolysis in Patients with Acute Cerebral Infarction Complicated with Atrial Fibrillation
Cardiogenic cerebral embolism is prone to occur in anterior circulation and large area infarction. Intravenous thrombolysis is currently the most effective treatment for ischemic stroke confirmed by evidence-based medicine, and the dosage of drugs is the key to treatment. This study was designed to evaluate the efficacy and safety of different doses of rt-PA intravenous thrombolysis in the treatment of acute anterior circulation cerebral infarction with atrial fibrillation. The results showed that after thrombolysis, the NIHSS scores of the two groups decreased significantly (P < 0.05), and there was no significant difference in NIHSS scores between the two groups at each time point after thrombolysis. The plasma prothrombin time increased significantly and fibrinogen decreased significantly in the full-dose group at 1 and 7 days after thrombolysis, compared with the low-dose group, the difference was significant (P < 0.05). There was no significant difference in the mortality rate between the low dose group and the sufficient dose group (P < 0.05). Conclusion: Intravenous thrombolytic therapy with rt1A in low dose group is safer for anterior circulation infarction with atrial fibrillation, which can reduce the risk of bleeding and improve the quality of life of patients with neurological deficits.